

Expediting the Diagnosis of Heart Attack with Atellica VTLi Patient-Side Analyzer for Industry First Fingerstick High-Sensitivity Troponin I at Point-of-Care

- **Expediting triage times for patients presenting with heart attack symptoms enhances patient care and helps against Emergency Department overcrowding – a patient safety issue and a world-wide public health problem that contributes to cardiac deaths.¹**
- **The Siemens Healthineers Atellica VTLi Patient-Side Analyzer is offering clinicians the first high-sensitivity troponin I test from a fingerstick sample.**
- **With the ability to aid in diagnosing a heart attack quickly and accurately in eight minutes, clinicians can improve outcomes for patients and healthcare providers.**

Siemens Healthineers announced today the company's Atellica VTLi Patient-Side Immunoassay Analyzer² has obtained CE mark and is expected to be available later this spring. The Atellica VTLi analyzer provides lab standard, high-sensitivity cardiac troponin I (hs-cTnI) test results to clinicians in eight minutes using a patient's fingerstick blood sample. With this industry first technology, Siemens Healthineers is helping to improve the patient care paradigm with its disruptive technology, providing hs-cTnI results at the patient's side to help clinicians properly diagnose and treat heart attacks with confidence.

“Siemens Healthineers is among the best-in-class with cardiac disease state solutions, immunoassays, and critical care diagnostics. Now we are raising the bar as the first company to offer a true point-of-care high-sensitivity cardiac troponin I test with results comparable to laboratory performance using just a fingerstick sample. Healthcare providers have been waiting decades for hs-cTnI at the point of care and now the wait is over. This new technology further expands Siemens Healthineers' broad cardiac portfolio throughout the entire patient care continuum,” said Christoph Pedain, PhD, Head of Point of Care Diagnostics, Siemens Healthineers.

Globally, millions of patients present annually to the emergency room with symptoms that may be related to a heart attack. Responsible for an estimated 31 percent of all deaths worldwide, cardiovascular disease is the leading cause of death.³ Fast triage for patients presenting with symptoms can help save lives. Clinicians primarily rely on the central laboratory for critical blood test results before they can make care decisions for their patients. This process can take an hour or more to get results. The substantial reduction in turnaround time achieved when introducing the wireless, handheld Atellica VTLi analyzer may offer clinicians a fast pathway to help diagnose and treat their patients, helping to accelerate care, improve patient outcomes, and reduce the strain felt in overcrowded EDs.

When a patient presents at the hospital with symptoms of a potential heart attack, securing favorable outcomes depends on the speedy availability of test results, and the confidence care providers have in them. "In today's busy emergency departments across the globe, there is a demand by clinicians for the rapid measurement of cardiac troponin, using guideline-recommended, high-sensitivity assays, to quickly and accurately rule in and rule out myocardial injury and myocardial infarction in patients presenting with symptoms suggestive of ischemia," said Dr. Fred Apple, PhD, Medical Director of clinical laboratories, clinical chemistry, point-of-care testing, and clinical and forensic toxicology laboratories at Hennepin County Medical Center. "The Siemens Healthineers Atellica VTLi point-of-care assay technology, utilizing whole blood with result turn-around times in as fast as eight minutes, provides a high-sensitivity cardiac troponin I measurement that is equivalent to the diagnostic and analytical accuracy of instruments found in the central laboratory. I believe this POC system could easily integrate into existing hospital and clinic workflows, with the potential to impact patient care and clinical outcomes, with operational and financial efficiencies."

The Atellica VTLi system has wireless capability that easily integrates and directly connects to data management systems, including the Siemens Healthineers POC Ecosystem Solution, and the laboratory and hospital information systems. Together, this offering provides the laboratory centralized control over decentralized point-of-care testing.

The Atellica VTLi immunoassay analyzer is the resulting innovation stemming from Siemens Healthineers' acquisition of Minicare BV, which was completed on July 2, 2019.

¹ What we have learned from a decade of ED crowding research. Pines, JM, Griffey RT, Acad Emerg Med. 2015 Aug;22(8):985-7. doi: 10.1111/acem.12716. Epub 2015 Jul 20

² The products/features (mentioned herein) are not commercially available in all countries. Not available for sale in the U.S.A. Their future availability cannot be guaranteed.

³ [https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-\(cvds\)](https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds))

This press release and a press picture are available at <https://www.corporate.siemens-healthineers.com/press/releases/atellica-vtli>

For further information please see [Atellica® VTLi Patient-side Immunoassay Analyzer \(siemens-healthineers.com\)](https://www.siemens-healthineers.com/atellica-vtli).

Contact for journalists

Thorsten Opderbeck

Phone: +49 173 617 8107; Email: thorsten.opderbeck@siemens-healthineers.com

Kimberly Nissen, Siemens Healthineers

Phone: +1 610 241-2129; Email: kimberly.nissen@siemens-healthineers.com

Follow the press team on Twitter: <https://twitter.com/siemenshealthpr>

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) is shaping the future of Healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company's foundation in in-vitro diagnostics, image-guided therapy, and in-vivo diagnostics. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers' ability to provide high-quality, efficient care to patients. In fiscal 2020, which ended on September 30, 2020, Siemens Healthineers, which has approximately 54,000 employees worldwide, generated revenue of €14.5 billion and adjusted EBIT of €2.2 billion. Further information is available at www.siemens-healthineers.com.